Literature DB >> 19084432

Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?

Ju Hyun Shim1, Joong-Won Park, Joon-Il Choi, Hyun-Beom Kim, Woo Jin Lee, Chang-Min Kim.   

Abstract

PURPOSE: To investigate risk factors and prognostic significance of postembolization fever (PEF)--a temperature of more than 38.0 degrees C--after chemoembolization in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: The authors retrospectively analyzed data from 442 patients with unresectable HCC who underwent their first session of chemoembolization without other procedure-related complications except postembolization syndrome between January 2005 and December 2006. Of the 442 patients, 362 (81.9%) were men and 80 (18.1%) were women; patients ranged in age from 28 to 86 years (median, 61 years).
RESULTS: PEF after chemoembolization developed in 91 patients (20.6%). Occurrence of PEF was closely associated with several clinical-laboratorial variables, although not with response to chemoembolization. With use of logistic regression analysis, however, a tumor size larger than 5 cm was the only independent factor related to PEF development (odds ratio, 8.192; 95% confidence interval [CI]: 3.641, 18.435; P < .001). Although PEF was not an independent predictor of progression-free survival, it significantly increased the risk of death by about 1.4-fold, in correlation with overall survival (hazard ratio, 1.378; 95% CI: 1.003, 1.893; P = .048).
CONCLUSIONS: PEF after chemoembolization in patients with HCC was strongly correlated with large tumor size and was a significant independent predictor of overall survival.

Entities:  

Mesh:

Year:  2008        PMID: 19084432     DOI: 10.1016/j.jvir.2008.10.021

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Response to Lo.

Authors:  Jong Woo Kim; Jin Hyoung Kim
Journal:  Am J Gastroenterol       Date:  2015-01       Impact factor: 10.864

2.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 3.  Treatment algorithms for managing hepatocellular carcinoma.

Authors:  Vivek A Saraswat; Gaurav Pandey; Sachin Shetty
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

4.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

5.  Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma.

Authors:  Chung Hwan Jun; Ho Seok Ki; Hoon Ki Lee; Kang Jin Park; Seon Young Park; Sung Bum Cho; Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

6.  Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Authors:  Jinpeng Li; Congcong Shi; Jutian Shi; Jinlong Song; Nan Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.